Funding for this research was provided by:
National Natural Foundation of China (U1801282, 81802382, 81702322, 82130080, 82273145)
Key-Area Research and Development Program of Guangdong Province (2019B020229002)
Guangdong Basic and Applied Basic Research Foundation (2021A1515010224)
China Postdoctoral Science Foundation (2021M690170, 2022T150749)
Received: 5 May 2022
Accepted: 11 November 2022
First Online: 6 December 2022
: This study has been approved by the Human Research Ethics Committees of Sun Yat-sen University (SYSKY-2022-120-01). All hepatocellular carcinoma patients have been informed of the study details and signed informed consent forms. All mice experiments were performed according to national and institutional guidelines from the Institutional Animal Care and Use Committees, and have been reviewed and approved by the Animal Ethical and Welfare Committee (AEWC) (Approval No. IACUC-AEWC-F2206018).
: We confirm: that this study described has not been published before; that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors.
: No potential conflicts of interest were disclosed by all co-authors.